DrugPatentWatch Database Preview
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
« Back to Dashboard
Iodophenyl is an investigational drug.
There have been 9 clinical trials for Iodophenyl. The most recent clinical trial was a Phase 2 trial, which was initiated on July 12th 2017.
The most common disease conditions in clinical trials are Parkinson Disease, Alcoholism, and Alcohol Drinking. The leading clinical trial sponsors are Cellectar Biosciences, Inc., Neurobiology Research Unit, Rigshospitalet, Copenhagen, and GE Healthcare.
There are two US patents protecting this investigational drug and twenty-eight international patents.
Recent Clinical Trials for Iodophenyl
|Trametinib and TAS-102 in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery||City of Hope Medical Center||Phase 1|
|Does Treatment With GLP-1 Reduce Alcohol Intake in Patients With Alcohol Dependence?||Neurobiology Research Unit, Rigshospitalet, Copenhagen||Phase 2|
|Does Treatment With GLP-1 Reduce Alcohol Intake in Patients With Alcohol Dependence?||Section of Biostatistics University of Copenhagen, Copenhagen||Phase 2|
Top disease conditions for Iodophenyl
Top clinical trial sponsors for Iodophenyl
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Iodophenyl||Start Trial||Method for preparing nilotinib||ASYMCHEM LABORATORIES (TIANJIN) CO., LTD (Teda Tianjin, CN) TIANJIN ASYMCHEM PHARMACEUTICAL CO., LTD (Tianjin, CN) JILIN ASYMCHEM LABORATORIES CO., LTD (Jilin, CN) ASYMCHEM LIFE SCIENCE (TIANJIN) CO., LTD (Teda Tianjin, CN) ASYMCHEM LABORATORIES (FUXIN) CO., LTD (Liaoning, CN)||Start Trial|
|Iodophenyl||Start Trial||Small molecules for the modulation of MCL-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders||Dana-Farber Cancer Institute, Inc. (Boston, MA)||Start Trial|
|Iodophenyl||Start Trial||Compound and organic light-emitting device including the same||Samsung Display Co., Ltd. (Yongin-si, KR)||Start Trial|
|Iodophenyl||Start Trial||Cationic polymerizable compositions and methods of use thereof||STRATASYS LTD. (Rehovot, IL)||Start Trial|
|Iodophenyl||Start Trial||Modulators of the retinoid-related orphan receptor gamma (ROR-gamma) for use in the treatment of autoimmune and inflammatory diseases||Glaxo Group Limited (GB)||Start Trial|
|Iodophenyl||Start Trial||Syk inhibitors||Gilead Sciences, Inc. (Foster City, CA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Iodophenyl||European Patent Office||3305777||2035-05-26||Start Trial|
|Iodophenyl||World Intellectual Property Organization (WIPO)||2016187824||2035-05-26||Start Trial|
|Iodophenyl||European Patent Office||2528893||2030-01-29||Start Trial|
|Iodophenyl||European Patent Office||3138838||2030-01-29||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|